These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34510471)

  • 1. Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus.
    Wu CT; Tsai YT; Jung HK; Fu SL; Hsiung CA; Liu HY; Lai JN
    J Clin Pharmacol; 2022 Feb; 62(2):276-284. PubMed ID: 34510471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.
    Hung SC; Chang YK; Liu JS; Kuo KL; Chen YH; Hsu CC; Tarng DC
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):605-14. PubMed ID: 26094107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
    PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
    Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
    Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
    Tseng CH
    Eur J Cancer; 2016 Jan; 52():19-25. PubMed ID: 26630530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
    Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
    Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
    Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
    Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
    Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.
    Sipahi S; Solak Y; Acikgoz SB; Genc AB; Yildirim M; Yilmaz U; Nalbant A; Tamer A
    Int Urol Nephrol; 2016 Aug; 48(8):1305-1312. PubMed ID: 27102431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.
    Kwon S; Kim YC; Park JY; Lee J; An JN; Kim CT; Oh S; Park S; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
    Diabetes Care; 2020 May; 43(5):948-955. PubMed ID: 32132005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Metformin Use With End-Stage Renal Disease in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study Under the Pay-for-Performance Program.
    Lee MC; Lee CH; Chang LY; Chang CH; Zhang JF; Lee MR; Wang JY; Chen SM
    J Clin Pharmacol; 2019 Nov; 59(11):1443-1452. PubMed ID: 31163098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.